PDF-8 September 2014EMA//2011Rev 1*Guideline on good pharmacovigilance pra

Author : giovanna-bartolotta | Published Date : 2017-02-22

Draft Revision 1 agreed by ERMS FG29 May 2013 Draft Revision 1 adopted by Executive Director6 June 2013 Released for public consultation7 June 2013 nd of consultation

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "8 September 2014EMA//2011Rev 1*Guideline..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

8 September 2014EMA//2011Rev 1*Guideline on good pharmacovigilance pra: Transcript

Draft Revision 1 agreed by ERMS FG29 May 2013 Draft Revision 1 adopted by Executive Director6 June 2013 Released for public consultation7 June 2013 nd of consultation deadline for comments5 August 2. If you have a question on signal managem ent that is not addressed in this document please send it to pv helpdeskemaeuropaeu Note his document has been produced for guidance only and should be read in conjunction with Directive 200183EC Regulation E Draft agreed by ERMS FG20 July 2012 Draft adopted by Executive Director25 July 2012 Start of public consultation6 July 2012 End of consultation (deadline for comments)21 September 2012 Revised draft f 9 April EMA/816573/2011Rev 1* Draft agreed by ERMS FG24 January 2012 Draft adopted by Executive Director20 February 2012 Released for consultation21 February 2012 End of consultation (deadline for co JAMASOFT2017. 1. Social. Pharmacy. Pharmacoepidemiology. Pharmacovigilance. JAMASOFT2017. 2. P. armacovigilance. system collects data . throughout the . lifecycle . of each . medicinal. . product. , MD. Pfizer, India. DISCLAIMER. Overview. Introduction & Terminology. Why Pharmacovigilance?. Pharmacovigilance Practices. : International & Indian. PVPI. Drug Safety Issues in Clinical Trials . Shanthi Pal. Leader, Medicines Safety. Safety . and Vigilance,. WHO, Geneva. What is pharmacovigilance. The science and activities relating to the detection, assessment, understanding and prevention of . Monitoring the safety of medicines. Pharmacovigilance is the science and practices related to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problem. Dr Shanthi Pal. . Group Lead, Medicines Safety . . Director/EMP . K. De . Joncheere. Coordinator PAU. G. Forte. Head/RHT. L.Rago. Coordinator/PHI. M Zafar. Coordinator /PQT. Coordinator RSS. N Dellepiane. Shanthi Pal. Leader, Medicines Safety. Safety . and Vigilance,. WHO, Geneva. What is pharmacovigilance. The science and activities relating to the detection, assessment, understanding and prevention of . Prospects and Challenges of Providing Pharmacovigilance Services in Resource Limited Countries Avong YK 1 , Jatau B 1 , Ekong E 1 , Ndembi N 1 , Okuma J 1 , Obieze AI 2 , Osakwe A 2 , Prospects and Challenges of Providing Pharmacovigilance Services in Resource Limited Countries Avong YK 1 , Jatau B 1 , Ekong E 1 , Ndembi N 1 , Okuma J 1 , Obieze AI 2 , Osakwe A 2 , ARVs: Focus on Toxicity Monitoring . and Surveillance of DTG during pregnancy to inform treatment policy . Adele Schwartz Benzaken. . Department . of . STI, . HIV/AIDS . and Viral . Hepatitis. Ministry . 1466 Nikhil GuptaKavita BahmaniAjit Jangra IntroductionPharmacovigilance and drug safety remains As per the World Health Organization (WHO), Pharmacovigilance may be dened ClinicalPractice ISSN Authors: . 1. Juliet Jokwiro, . 1. Nicole Chekudambune-Kawaza, . 1. Kenny Sithole, . 1. Bongani Dube, . 2. Charles Sandy, . 2. Manners Ncube, . 2 . Regina Mubau,. 2. Chlorata Gwanzura, . 2. Kwenziweyinkosi Ndlovu, .

Download Document

Here is the link to download the presentation.
"8 September 2014EMA//2011Rev 1*Guideline on good pharmacovigilance pra"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.